Basdevant, Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment, Diabetes & Metabolism, Volume 33, Issue 1, February 2007, Pages 13-24, ISSN 1262-3636, Eussen SM, de Groot LM, Clarke R, et al
The trial was designed to show the contribution of the GLP-1 component to glycemic lowering and the insulin glargine dose and the dosing algorithm was selected to isolate the effect of the GLP-1 component
Si han pasado ms de 4 das desde la dosis programada, omitir esa dosis y administrar la siguiente segn el calendario regular
The GEP12 doseresponse (0.1100 nM) binding assay was performed in a duplicate
Research overview Related protocols and comparisons BPC-157 (5 mg Vial) Dosage Protocol BPC-157 (10 mg Vial) Dosage Protocol BPC-157 + TB-500 (20 mg Blend) Dosage Protocol TB-500 (5 mg) + BPC-157 (5 mg) Stack Dosage Protocol Tri-Heal (45 mg Blend) Dosage Protocol GLOW (70 mg Blend) Dosage Protocol KLOW (80 mg Blend) Dosage Protocol TB-500 (5 mg Vial) Dosage Protocol